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CABG redo increasingly become more and more important both
clinically and economically. METHODS: A retrospective study
was conducted among a population of 256,806 patients with
initial CABG performed during the time period of January 2001
to February 2005. Data were collected from 332 hospitals out
of the Solucient® ACTrackerTM inpatient database. Multivariate
logistic regression was used to identify factors contributed to
CABG performance and propensity score adjustment was
applied. Patient demographic, hospital characteristics (hospital
bed size, region, teaching and PCI annual volume), disease con-
dition (Chronic Obstructive Pulmonary Disease, COPD; Periph-
eral Vascular disease, PVD; Diabetes Mellitus, DM and
Malignancy, MA), related therapeutic drugs class (Anticoagu-
lant, Antiplatelet, GP2b3a, Asprin and Statins) usages during
hospital stay, patient severity and risk adjust mortality index and
on and off pump were introduced to logistic regression analysis.
RESULTS: The patient demographics, hospital characteristics
and disease conditions were controlled for comparison between
CABG and CABG redo population (P > 0.05) except that male
tended to have more CABG redo (OR: 1.2977, CI:
1.0956–1.5371). A total of 581 (0.22%) patients were found to
have undergone CABG redo in an average of 350 days. Con-
comitant drug uses were studied. Anitcoagulant (OR: 3.649, CI:
3.353–3.971) and GP2b3a (OR: 1.480, CI: 1.331–1.647) have
been found to not help with outcomes of the CABG patient while
Asprin (OR: 0.308, CI: 0.28–0.335) and Statin (OR: 0.544, CI:
0.506–0.585) were found to signiﬁcantly impact the outcomes
of CABG performance. CONCLUSIONS: The study conﬁrmed
that patients with CABG redo had worse outcomes than those
with one CABG (5.34% vs. 3.03%, p < 0.01). Detail drug usage
studies are recommended to ﬁnd out how to prevent patients
from CABG redo in the initial treatment.
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THE IMPACT OF MYOCARDIAL PERFUSION IMAGING FOR
DETECTION OF CORONARY ARTERY DISEASE ON THE
HEALTH OUTCOMES OF ASYMPTOMATIC PATIENTS WITH
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OBJECTIVE: The objective of this investigation is to determine
whether the results of myocardial perfusion imaging (MPI) for
detection of coronary artery disease (CAD) results in improved
new health outcomes in asymptomatic patients with Type-2 dia-
betes. The potential value of MPI is highlighted by the demon-
strated association between patients with diabetes mellitus and
the accelerated development of CAD, the fact that myocardial
ischemia due to coronary atherosclerosis is commonly asympto-
matic and the proven improvement in health outcomes in
patients treated with coronary artery bypass grafting (CABG).
METHODS: A retrospective observational study was conducted
using data from a Veterans’ Health System database, which
included detailed diagnosis codes and three-year clinical follow-
up of out-patient and in-patient encounters. We examined
whether the presence of coded diagnoses for angina in patients
also diagnosed with diabetes was associated with increased coro-
nary artery abnormalities detected by MPI; we also examined the
rates of cardiac intervention and subsequent cardiac events. A
total of 517 patients who underwent MPI during the observa-
tion interval were included in the analysis; 520 matched patients
who did not undergo MPI were used for comparison. RESULTS:
Over 31.9% of MPI studies were abnormal and indicated
ischemic or ﬁxed perfusion defects, or both. Forty-one patients
in the MPI cohort experienced cardiac death and 66 suffered MI,
whereas in the comparator cohort 68 (OR 2.4 [95% CI
1.4–6.2]); p < 0.01) suffered cardiac death and 97 suffered MI
(OR 4.4 [95% CI 2.6–9.6]; p < 0.01). The rate of CABG was
approximately four-fold greater in the MPI cohort and the rate
of both PTCA and CABG was three-fold greater in the MPI
cohort. CONCLUSION: Findings from this retrospective analy-
sis of MPI in asymptomatic patients with CAD and Type-2 dia-
betes has demonstrated that MPI resulted in interventions that
reduced hard and soft cardiac events.
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A NATIONAL STUDY PREDICTING THE INFLUENCE OF
PAYMENT SOURCES ON THE THIAZIDE DIURETICS
UTILIZATION FOR HYPERTENSION
Rahman A
Shenandoah University, Winchester,VA, USA
OBJECTIVES: It costs $12 billion annually for the management
of hypertension in U.S. Drug therapy is a major cost associated
with the management of hypertension. The Seventh Report of
the Joint National Committee on Prevention, Detection, Evalu-
ation, and Treatment of High Blood Pressure (JNC-7) issued new
guidelines for hypertension management. One of their guidelines
is that thiazide-type diuretics should be used in the therapy of
most patients with hypertension either alone in combination
with other drugs. Diuretics enhance the efﬁcacy of the multidrug
regimens and are more affordable than other antihypertensive
agents. Despite these recommendations, thiazide diuretics remain
underused. Literature review indicates that patient’ payment
sources might inﬂuence the drug utilization for hypertension.
This study examines the inﬂuence of various patients payment
source on the thiazide diuretics utilization for hypertension in
hospital ambulatory setting. METHODS: Patient payment
sources such as Self Pay, Medicare, Medicaid, HMO’s, and PPO’s
were used as independent variables to determine their inﬂuence
on the thiazide diuretics utilization for hypertensive patients.
Data from the National Hospital Ambulatory Medical Care
Survey (NHAMCS) 2003 were utilized. Patients with principal
diagnosis of Hypertension (ICD-9 code 401–404) were analyzed
using ANOVA, multiple linear and binomial logit regression
models. RESULTS: Hypertensive Patients with Federal source of
payments (Medicaid and Medicare) were prescribed signiﬁcantly
lower number of thiazide diuretics compared to patients with
other sources of payments (R2 = 0.116). Patients with (HMO’s
+ PPO’s) and self-pay as their primary source of payments 
were prescribed signiﬁcantly higher number of thiazide diuretics
compared to patients with other source of payments (R2 = 0.364)
and (R2 = 0.287) respectively. CONCLUSIONS: Thiazide diuret-
ics utilization for hypertensive patients are signiﬁcantly 
inﬂuenced by patients’ source of payments. Patients with
HMO’s, PPO’s and self-pay as their source of payment 
appears to appropriately adhere to the (JNC-7) guidelines for
hypertension.
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OBJECTIVES: Underused and inadequate care can adversely
affect patient health. Missed opportunities often occur in
primary care because process ﬂow models are not optimized to
make effective use of established clinical knowledge. To bridge
the gap between knowledge and practice we tested an electronic
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health record based process to routinely assess and manage car-
diovascular disease (CVD) risk. METHODS: This project was
pilot tested in one Geisinger Clinic using EpiCare’s® EHR
system. Five computerized procedures were tested during routine
encounters to: 1) Deploy an automated protocol to identify
patients meeting criteria for CVD risk assessment; 2) determine
data elements missing to assess heart attack risk; 3) automati-
cally consent and order lab and patient self-reported risk ques-
tionnaires to assess risk; 4) activate a modiﬁed Framingham
CVD formula to calculate individual patient risk; and 5) engage
patients at moderate to high risk to review risk factors and deﬁne
goals. RESULTS: Over a 12-month period, 1610 patients were
eligible for screening, all of whom were missing data on one or
more CVD risk factors. Of these, orders for labs and question-
naire were placed for 27%; of these, 93% completed some or all
measures and 86% of those asked completed the online risk
assessment questionnaires. Using a modiﬁed Framingham risk-
scoring algorithm, 36% patients who were fully assessed, were
at moderate or high risk of a heart attack and were scheduled to
set goals to reduce their risk. Almost half of these patients com-
pleted their goal setting module. Goals were ﬁled back to the
EHR as a reference for monitoring patient progress. CONCLU-
SIONS: This preliminary test of a new model for CVD risk man-
agement suggests that automated protocols based on the EHR
can be used to routinely identify, assess and manage cardiovas-
cular disease risk. Primary care physicians can use EHR based
processes to improve patient management.
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OBJECTIVES: Non-achievement of combined optimal lipid
values (OLVs; LDL-C, HDL-C, and triglyceride [TG]) is associ-
ated with a 45% increase in cardiovascular events. Multiple lipid
abnormalities may require combination therapy, however sparse
data are available comparing marketed combination products
(extended release niacin/lovastatin [ERN/L] and simvastatin/eze-
timibe [S/E]). We modeled OLV attainment with ERN/L, S/E, and
components within a managed care (MCO) database.
METHODS: Patients were selected from a 2.1 million record
database based on: lipid panel between 1/1/00 and 12/31/01, no
concomitant lipid therapy, and continuous eligibility for 24
months. Initial lipid values and cardiovascular risk status (deter-
mined by ICD-9/CPT codes, prescription records) for each
patient was identiﬁed, and treatment effects were modeled using
product labeling at maximum doses. OLVs were based upon
NCEP ATP-III, AHA Women’s guidelines, or ADA guidelines.
RESULTS: We analyzed 44,351 patients; 50% male, age 65 + 13
years, and baseline lipids: LDL-C 131 + 35mg/dL, HDL-C 48 +
15mg/dL, TG 159 + 77mg/dL. At baseline, 10.1% achieved
OLVs which increased with ERN/L 56.1%, S/E 48.4%, ERN
36.4%, L 35.6%, S 42.3%, and E 18.4% (chi-square p < 0.05
all vs baseline; ERN/L vs S/E, ERN, and L; S/E vs S and E). In
2° prevention (N = 20,948), OLV increased from 8.2% to 51.1%
ERN/L, 50.4% S/E, 27.9% ERN, 31.8% L, 45.0% S, 17.7% E
(p < 0.05 for vs baseline; ERN/L vs ERN and L; S/E vs S and E).
In diabetes (N = 8,164), OLV increased from 7.4% to 50.5%
ERN/L, 46.0% S/E, 28.2% ERN, 30.2% L, 41.9% S, 16.4% E
(p < 0.05 all vs baseline; ERN/L vs S/E, ERN, and L; S/E vs E),
with similar results in 1° prevention (N = 23,403). CONCLU-
SIONS: In this MCO population, OLVs were best achieved with
ERN/L versus S/E. In a broad sprectrum of risk populations,
ERN/L achieved signiﬁcantly greater OLVs than each of it’s indi-
vidual components, in contrast to S/E.
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OBJECTIVE: This prospective, observational study evaluates the
medication utilization patterns and cost of treatment of patients
treated for myocardial infarction (MI) at a government institu-
tion in Kerala, India. METHODS: Patients with a diagnosis of
MI and received streptokinase (SK) therapy are enrolled into the
study. The following data is collected: demographics, clinical
outcomes, laboratory results, ECG resolution, drug utilization
parameters, and cost data from a patient perspective. The cost
of drug therapy for each patient is calculated utilizing the
Current Index of Medical Specialties 2004. Logistic regression
univariate analysis is conducted to determine the association
between outcome and treatment factors with p < 0.05.
RESULTS: One hundred ﬁfty patients are enrolled. The mean
age is 59.1 years and 77% of the patients are male. The average
pain to treatment period for SK therapy is 4.69 hours, while the
average door to treatment period is 79.9 minutes. A total of
34.7% of the patients experience a post SK ECG resolution
above 70% and in hospital mortality is 12.67%. Logistic regres-
sion results indicate that greater than 70% resolution on ECG
is associated with shorter treatment window period, non ante-
rior infarct, dyslipidemia, lower CPK-1 level, and lower rate of
mortality. Increased mortality is associated with heart block,
hypotension, low ECG resolution, arrhythmias, low ejection
fraction, CHF, and less use of beta blockers, nitrates, ace
inhibitors, and atorvastatin. The average cost of care to the
patient is Rs 5600.15 (SD Rs 13762.87). The average cost to the
hospital for free medicines is Rs 2629.06 (SD Rs 1515.22).
Patients who had at least 70% ECG resolution have an average
cost of Rs 4090.28, while patients who had less have an average
cost of Rs 5539.98. CONCLUSION: Management of myocar-
dial infarction utilizing SK appears to improve clinical outcomes
and be cost-effective in a government setting in Kerala, India.
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TREATED WITH NESIRITIDE
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OBJETIVES: Nesiritide is indicated for the intravenous treat-
ment of patients with acutely decompensated heart failure who
have dyspnea at rest or with minimal activity. In a recent study
it was recommended the drug be used only for inpatient settings.
We investigated effectiveness of Nesiritide in a group of Con-
gestive Heart Failure (CHF) inpatients using Solucient’s
ACTracker inpatient database. METHODS: A cohort of 28,332
Congestive Heart Failure patients discharged from 21 hospitals
from 4/2003 to 6/2005 was selected with 7,668 patients treated
with nesiritide as study group and a comparison group of 20,664
non Nesiritide treated patients. Chi-Square and t tests were used
to compare the two groups for mortality rate and hospital length
of stay (LOS) respectively. Conditional Logistic regression was
